Pre-market hot trades in US stocks: Power REIT pre-market down 13.58%; Synopsys pre-market up 3.90%

Pre-market Hot Trades in US Stocks Synopsys is up 3.90% in pre-market trading. According to recent key news: On September 17, Hong Kong Chief Executive John Lee proposed the establishment of an "AI Efficiency Enhancement Group" in the Policy Address to improve government efficiency. This news has driven up the stock prices of AI-related companies. On September 16, Synopsys director Robert G. Painter purchased company shares, showing insider confidence in the company's prospects and boosting market sentiment. On September 16, Baird downgraded its rating on Synopsys, citing weak growth expectations for the IP business and unclear prospects. Nevertheless, the overall market remains optimistic about the company's long-term strategy. The application prospects of AI technology are broad, and market sentiment is positive. Top Gainers in Pre-market US Stocks 89bio is up 84.03% in pre-market trading. According to recent key news: On September 18, Roche announced it would acquire 89bio for up to $3.5 billion. The acquisition includes a cash payment of $14.50 per share and up to $6.00 per share in contingent value rights, with a total transaction value of up to $3.5 billion. This news led to a significant increase in 89bio's stock price in pre-market trading. On September 18, 89bio's board has approved the acquisition agreement and recommended shareholders accept the tender offer. The transaction is expected to be completed in the fourth quarter of 2025. On September 18, analysts rated 89bio's stock as a strong buy, with a target price of $27, indicating a potential upside of 234.16%. Recent merger and acquisition activities in the biopharmaceutical industry have been frequent. Aptevo Therapeutics is up 72.34% in pre-market trading. Based on recent important news: On September 16, Aptevo Therapeutics announced that the third cohort of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate, leading to a 57% increase in stock price. The study tested Aptevo's CD123 x CD3 bispecific antibody in combination with venetoclax and azacitidine for newly diagnosed AML patients. On September 16, Aptevo's trading volume surged, with 34 million shares traded that day, significantly higher than the three-month daily average of about 165,000 shares. On September 17, despite facing financial performance challenges, including declining revenue, high leverage, and negative cash flow, Aptevo's positive progress in its oncology pipeline provides potential upside. The biotechnology industry is highly volatile and requires caution. AquaBounty Technologies is up 33.33% in pre-market trading. According to recent key news: On September 18th, technical analysis of AquaBounty Technologies showed a neutral outlook, with mixed momentum indicator signals. The negative price-to-earnings ratio and lack of dividends further affected the stock's attractiveness. Improvements in operational efficiency and cash flow management are crucial for enhancing its financial health. AquaBounty Technologies focuses on the development and commercialization of genetically modified fish to improve aquaculture productivity. The current market capitalization is $4.3 million, with an average trading volume of 2,134,395. The biotechnology industry has shown recent volatility